MAM
CRBU icon

Mark Asset Management’s Caribou Biosciences CRBU Stock Holding History

Mark Asset Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-80,000
Closed -$1.91M – 52
2021
Q3 		$1.91M Buy
+80,000
New +$1.96M 0.21% 44

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Mark Asset Management's CRBU Position: Q4 2021 in Review

Mark Asset Management sold out of Caribou Biosciences (CRBU) in Q4 2021, closing a stake of 80,000 shares — an estimated $1.91M sold.

Mark Asset Management first reported a position in CRBU in Q3 2021 and held it in 1 quarter. The position peaked at $1.91M in Q3 2021. 93 funds tracked by Wall St. Rank hold CRBU as of Q4 2021.

  • Mark Asset Management reported no remaining Caribou Biosciences position as of Q4 2021 after selling out during the quarter.
  • Mark Asset Management sold 80,000 Caribou Biosciences shares in Q4 2021, an estimated $1.91M.
  • Mark Asset Management first reported a position in Caribou Biosciences in Q3 2021 and held it in 1 quarter.
  • Mark Asset Management's Caribou Biosciences position peaked at $1.91M in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2021.

Based on Mark Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.